Molecular Partners AG & NuMeRI, presentation Feb. 2026The Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in that direction. The collaboration aims to develop and manufacture so-called Radio-DARPin therapeutics, in which targeted protein molecules deliver radioactive isotopes directly to tumours. Early clinical data on the DARPin molecules in combination with radioisotopes suggest targeted tumour localisation. Proof of efficacy, however, is still pending.
Tag Archive for: Radiopharmaceuticals
Van Overeem Nuclear BVRadiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development.
Nuclidium AGBasel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
Actithera Norway ASThe biotech company Actithera, with locations in Cambridge, USA, and Oslo, Norway, has successfully closed a major Series A round, raising US $75.5 million. Its isotope-agnostic platform — designed with a specific focus on the interaction between linker and target molecule — has attracted strong interest from a wide range of investors. However, the path to this achievement was not as straightforward as anticipated, CEO Andreas Goutopoulos told European Biotech News.